Last month Bayer announced that BAY 86-6150, its investigational recombinant factor VIIa (rFVIIa) product for the treatment of patients with hemophilia A or hemophilia B, and inhibitors, is being investigated in a Phase II/III clinical study called TRUST (TReatment with Unique recombinant rFVIIa STudy).

 

Recruitment for the first group of patients has been completed, but that for an additional three groups is ongoing. Sites in the US and internationally are ready to enroll eligible patients. The TRUST trial is designed to evaluate the safety and efficacy of BAY 86-6150. 

 

“Bayer is committed to finding innovative ways to meet the needs of people with hemophilia, including those affected by the effects of inhibitors to clotting factor replacement therapies,” said Pamela Cyrus, MD, Vice President and Head, US Medical Affairs, Bayer HealthCare Pharmaceuticals.

 

PRNewswire, November 28, 2012